Wire device for treating vascular defects

Abstract

The invention relates to a device and a method for treating a vasculature of a patient. Embodiments may include a permeable implant having a radially constrained state configured for delivery within a catheter lumen, an expanded state, and a plurality of filaments braided together. The permeable implant may include a harder proximal portion configured to be located at the neck of an aneurysm. The harder proximal portion may include a coil, a reinforcing element, or a reinforcing element disposed around or associated with or woven with the wire.

Description

[0001] This application is a divisional application of the invention patent application entitled “Silk device for treating vascular defects”, with an international application date of March 12, 2020, an international application number of PCT / US2020 / 022275, and a national application number of 202080020628.1. Technical Field

[0002] Embodiments of the devices and methods herein relate to preventing fluid flow through a tubular vessel or into a saccular cavity or small interior chamber of a vascular defect in a mammal. More specifically, embodiments herein relate to devices and methods for treating a vascular defect in a patient, including some embodiments specifically directed to treating a cerebral aneurysm in a patient. Background Art

[0003] The mammalian circulatory system consists of a heart that acts as a pump and a system of blood vessels that deliver blood to all parts of the body. Due to the forces exerted on the vessels by the flowing blood, a variety of vascular defects may occur in the blood vessels. One common vascular defect known as an aneurysm is due to the abnormal enlargement of a blood vessel. Typically, a vascular aneurysm forms due to weakening of the blood vessel wall and subsequent bulging and dilation of the vessel wall. For example, if an aneurysm is present within a cerebral artery, and the aneurysm can rupture and cause intracranial bleeding, death may occur.

[0004] Surgical techniques used to treat brain aneurysms typically involve a craniotomy that requires the creation of an opening in the patient's skull through which the surgeon can insert instruments to operate directly on the patient's brain. For some surgical approaches, the brain must be retracted to expose the parent blood vessel from which the aneurysm arises. Once the aneurysm is reached, the surgeon places a clip across the neck of the aneurysm, thereby preventing arterial blood from entering the aneurysm. With the clip properly placed, the aneurysm will disappear within a few minutes. Surgical techniques can be an effective treatment for many aneurysms. Unfortunately, the surgical techniques used to treat these types of conditions include major invasive surgical procedures that often require extended time under anesthesia, which carries high risks for the patient. Therefore, such surgeries require that the patient be in generally good physical condition in order to be a candidate for such surgery.

[0005] A variety of alternative and less invasive procedures have been used to treat brain aneurysms without resorting to major surgery. One method of treating aneurysms without invasive surgery involves placing a sheath or stent into a blood vessel and across the area where the aneurysm occurs. Such devices maintain blood flow through the vessel while reducing the blood pressure applied to the inside of the aneurysm. Some types of stents are expanded to the appropriate size by inflating a balloon catheter, known as balloon-expandable stents, while other stents are designed to expand elastically in a self-expanding manner. Some stents are typically covered with a sheath of polymer material called a graft to form a stent-graft. Stents and stent-grafts are typically delivered to a preselected location near the vascular defect via a delivery catheter. In the treatment of cerebral aneurysms, the use of covered stents or stent-grafts is very limited due to the possibility of inadvertent occlusion of small perforating vessels near the vascular defect being treated.

[0006] Furthermore, currently uncovered stents are often inadequate as a stand-alone treatment. To allow stents to pass through the microcatheters used in small cerebrovascular vessels, their density is often reduced so that only a small amount of the stent structure bridges the aneurysm neck when expanded. As a result, they do not block flow enough to cause blood clotting in the aneurysm and are therefore often used in conjunction with a vascular occlusive device (such as the coils mentioned above) to achieve aneurysm occlusion.

[0007] Some procedures involve delivering embolic or filling materials into the aneurysm. The delivery of such vascular occlusive devices or materials can be used to promote hemostasis or to completely fill the aneurysm cavity. Vascular occlusive devices can be placed within the body's vascular system, usually by catheter, to block blood flow through the vessel with the aneurysm by the formation of an embolism, or to form such an embolism within the aneurysm originating from the vessel. A variety of implantable coil-type vascular occlusive devices are known. The coils of such devices can themselves be formed into a secondary coil shape, or any of a variety of more complex secondary shapes. Vascular occlusive coils are commonly used to treat cerebral aneurysms, but have several limitations, including poor packing density, compaction due to the hydrodynamic pressure of blood flow, poor stability of wide-necked aneurysms, and complex and difficult deployment due to the fact that most aneurysm treatments by this method require the deployment of multiple coils. Coils are less effective in treating certain physiological conditions, such as wide-necked cavities (such as wide-necked aneurysms), because the risk of the coils migrating out of the treatment site is greater.

[0008] Many aneurysm neck bridging devices with defect spanning segments or regions have been attempted, however, none of these devices have had a significant measure of clinical success or use. The major limitation to their adoption and clinical utility is the inability to position the defect spanning segment to ensure coverage of the neck. Existing stent delivery systems that are neurovascular compatible (i.e., deliverable via microcatheter and highly flexible) do not possess the necessary rotational positioning capability. Another limitation of many aneurysm bridging devices described in the prior art is poor flexibility. The cerebral vasculature is tortuous, requiring a high degree of flexibility for effective delivery to most aneurysm locations in the brain.

[0009] What is needed is a device and method for delivery and use in small and tortuous blood vessels that can substantially block blood flow into an aneurysm, such as a cerebral aneurysm, and reduce the risk of unexpected aneurysm rupture or vessel wall injury. Additionally, what is needed is a method and device suitable for blocking blood flow in a cerebral aneurysm for an extended period of time without significant risk of deformation, compaction, or dislocation.

[0010] Endovascular occlusive devices are part of a new class of occlusive devices used to treat a variety of endovascular diseases, including aneurysms. They are generally more effective in treating these wide-necked diseases or larger treatment areas. Endovascular devices include a structure that sits within the aneurysm and provides an occlusive effect at the neck of the aneurysm to help restrict blood flow into the aneurysm. The remainder of the device includes a relatively conformable structure that sits within the aneurysm and helps occlude all or part of the aneurysm. Endovascular devices generally conform to the shape of the treatment site. These devices also occlude a cross-section of the neck of the treatment site / aneurysm, thereby promoting clotting over time and causing thrombosis and aneurysm closure.

[0011] These endovascular devices are difficult to design for a variety of reasons. For neurovascular aneurysms, these endovascular devices are particularly small, and any protruding structure of the endovascular device may puncture the vessel or tissue, causing additional complications. In larger aneurysms, there is also a risk of compaction, where the endovascular device can migrate into the aneurysm and out of the neck area. There is a need for endovascular devices that can address these issues. Summary of the invention

[0012] An intravascular occlusive device is described that is useful for treating a variety of conditions, including aneurysms and neurovascular aneurysms. It is often beneficial to have some stiffness in the proximal region of the intravascular device to promote proper seating of the device at the neck of the aneurysm and to prevent migration into the aneurysm. It is also often beneficial to have high flow disruption in the proximal or neck-adjacent region of the occlusive device to limit blood flow into the aneurysm. One way to increase flow disruption in the neck region and prevent potential migration issues is to increase the stiffness of the proximal portion of the intravascular device. The following embodiments incorporate coils, springs, or similar components into the proximal mesh portion of the intravascular device to increase stiffness and flow disruption along the proximal portion of the intravascular occlusive device.

[0013] In one embodiment, a device for treating a cerebral aneurysm in a patient is described. The device includes an elastic self-expandable permeable shell, the shell including a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state having a longitudinally shortened configuration relative to the radially constrained state, and a plurality of filaments braided together to form a mesh and define a lumen of the permeable shell, the expanded state having a proximal portion and a distal portion, wherein the proximal portion includes at least one coil or spring-like element (e.g., a helical coil or a complex, three-dimensional shaped coil) coupled to or incorporated into or with the mesh.

[0014] In another embodiment, a method for treating a cerebral aneurysm with a lumen and a neck is described. The method includes the step of advancing an implant in a microcatheter to an area of ​​interest in a cerebral artery, wherein the implant includes an elastic self-expanding permeable shell, the shell includes a radially constrained elongated state configured for delivery in the lumen of the microcatheter, an expanded state with a longitudinal shortening configuration relative to the radially constrained state, and a plurality of filaments, the filaments are woven together to form a net and define the cavity of the permeable shell, the expanded state has a proximal portion and a distal portion, wherein the proximal portion includes at least one coil connected to the net, wherein the implant is in a radially constrained elongated state in the microcatheter. The implant is then deployed in the cerebral aneurysm, wherein the permeable shell expands to an expanded state in the lumen of the aneurysm. The microcatheter is then withdrawn from the area of ​​interest after the implant is deployed.

[0015] In another embodiment, a device for treating a cerebral aneurysm in a patient is described. The device includes a resilient self-expandable permeable shell including a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state having a longitudinally shortened configuration relative to the radially constrained state, and a plurality of filaments braided together to form a mesh and define a lumen of the permeable shell, wherein the expanded state has a proximal portion and a distal portion, and wherein the proximal portion includes at least one coil connected to the mesh.

[0016] In another embodiment, a method for treating a cerebral aneurysm having an inner cavity and a neck is described. The method includes the step of advancing an implant in a microcatheter to an area of ​​interest in a cerebral artery, wherein the implant includes an elastic self-expanding permeable shell, the shell including an elongated state of radial constraints configured for delivery in the catheter lumen, an expanded state with a longitudinal shortening configuration relative to the radial constraint state, and a plurality of filaments, the filaments being woven together to form a net and defining a cavity of the permeable shell, wherein the expanded state has a proximal portion and a distal portion, and wherein the proximal portion includes at least one coil connected to the net. The implant is then deployed in the cerebral aneurysm, wherein the permeable shell expands to an expanded state in the inner cavity of the aneurysm. The microcatheter is then withdrawn from the area of ​​interest after the implant is deployed.

[0017] In another embodiment, a device for treating a cerebral aneurysm in a patient is described. The device includes a resilient self-expandable permeable shell including a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state having a longitudinally shortened configuration relative to the radially constrained state, and a plurality of filaments braided together to form a mesh and define a lumen of the permeable shell, wherein the expanded state has a proximal portion and a distal portion, and wherein the proximal portion includes one or more reinforcing elements to increase proximal stiffness of the device.

[0018] In another embodiment, a method for treating a cerebral aneurysm with an inner cavity and a neck is described. The method includes the step of advancing an implant in a microcatheter to an area of ​​interest in a cerebral artery, wherein the implant includes an elastic self-expanding permeable shell, the shell includes a radially constrained elongated state configured for delivery in the catheter lumen, an expanded state with a longitudinal shortening configuration relative to the radially constrained state, and a plurality of filaments, the filaments are woven together to form a net and define the cavity of the permeable shell, wherein the expanded state has a proximal portion and a distal portion, and wherein the proximal portion includes one or more reinforcing elements to increase the proximal stiffness of the device. The implant is then deployed in the cerebral aneurysm, wherein the permeable shell expands to an expanded state in the lumen of the aneurysm. The microcatheter is then withdrawn from the area of ​​interest after the implant is deployed.

[0019] In another embodiment, a device for treating a cerebral aneurysm in a patient is described. The device includes an elastic self-expanding mesh including a radially constrained elongated state configured for delivery within a catheter lumen and an expanded state having a longitudinally shortened configuration relative to the radially constrained state, wherein the mesh is formed from a plurality of filaments interlaced to define a lumen therein, the mesh having a plurality of pores and a proximal portion and a distal portion, and wherein the proximal portion of the mesh includes one or more reinforcing elements such that a proximal porosity of the mesh is less than a distal porosity of the mesh.

[0020] In another embodiment, a method for treating a cerebral aneurysm having an inner cavity and a neck is described. The method includes the steps of advancing an implant in a microcatheter to an area of ​​interest in a cerebral artery, wherein the implant includes an elastic self-expanding mesh, the mesh including an elongated state of radial constraints configured for delivery in the catheter lumen and an expanded state with a longitudinal shortening configuration relative to the radial constraint state, wherein the mesh is formed by a plurality of interwoven filaments defining a cavity therein, the mesh having a plurality of holes and a proximal portion and a distal portion, and wherein the proximal portion of the mesh includes one or more reinforcing elements such that the proximal porosity of the mesh is less than the distal porosity of the mesh. The implant is then deployed in the cerebral aneurysm, wherein the mesh expands to an expanded state in the lumen of the aneurysm. The microcatheter is then withdrawn from the area of ​​interest after the implant is deployed.

[0021] The at least one coil (e.g., having a spiral or three-dimensional complex shape), reinforcing element, or reinforcing element can be coupled to the mesh in a variety of ways. The at least one coil, reinforcing element, or reinforcing element can be arranged around at least one wire of the mesh, or the at least one coil can be woven with the wire to form the mesh. The at least one coil, reinforcing element, or reinforcing element can have a lumen extending therethrough and at least a portion of the wire can be disposed in the lumen. The at least one coil, reinforcing element, or reinforcing element can be incorporated into at least about 40% to about 100%, or about 50% to about 90%, or about 40% to about 80% of the proximal portion of the device.

[0022] The at least one coil, reinforcing element or reinforcing element may be a plurality of coils, reinforcing elements or reinforcing elements. For example, the at least one coil, reinforcing element or reinforcing element may include at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 coils, reinforcing elements or reinforcing elements. The at least one coil, reinforcing element or reinforcing element may include about 2 to about 10, about 3 to about 12, about 4 to about 8, about 5 to about 10, or about 5 to about 15. The at least one coil, reinforcing element or reinforcing element may be made of a variety of materials. For example, shape memory metal materials such as nitinol or stainless steel may be used. Radiopaque materials such as platinum, platinum alloys (e.g., platinum-tungsten), gold or palladium may be used. Composite materials such as stretched filling lines (e.g., radiopaque cores such as platinum surrounded by nitinol sheaths) made of a variety of materials may also be used to help improve radiopacity. The at least one coil, reinforcing element or reinforcing element may also have a three-dimensional coil shape, such as a spiral or other three-dimensional shape, wherein the three-dimensional coil is arranged around the wire of the mesh device. A three-dimensional shape, such as a helical shape or a 3D shape, increases the overall diameter of the proximal wire around which it is disposed. This increases the effective diameter of the wire in the proximal region of the device. This increase in diameter directly contributes to increased stiffness, which is based on a stiffness relationship to the fourth power of the wire diameter.

[0023] The stiffness of the proximal portion including the at least one coil, reinforcing element or stiffening element is greater than the stiffness of the distal portion of the device not including any coil. In one example, the radial and / or axial stiffness of the proximal portion of the device including the at least one coil may be between 1.5 and 3 times that of the distal portion of the device.

[0024] The device may also include a hydrogel incorporated into the proximal portion of the permeable shell. The at least one coil, reinforcing element, or stiffening element may be coated with a hydrogel, or a hydrogel may be placed within a lumen defined by the coil, reinforcing element, or wound nest of stiffening elements. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 is a front view of an embodiment of a device for treating a patient's vasculature and a plurality of arrows indicate inward radial forces.

[0026] Figure 2 is a front view of a beam supported by two simple supports, with arrows indicating the forces acting on the beam.

[0027] Figure 3 is a bottom perspective view of an embodiment of a device for treating a patient's vasculature.

[0028] Figure 4 yes Figure 3Front view of a device for treating the vascular system of a patient.

[0029] Figure 5 yes Figure 4 The device along Figure 4 A cross-sectional view taken along line 5-5 in FIG.

[0030] Figure 6 Along Figure 4 The longitudinal section taken along the center line 6-6 shows Figure 4 device.

[0031] Figure 7 is from Figure 5 The circled portion 7 is shown as an enlarged view of the resulting braided wire structure.

[0032] Figure 8 is from Figure 6 An enlarged view of the resulting braided wire structure is shown with the circled portion 8 being shown.

[0033] Fig. 9 yes Figure 3 Proximal view of the device.

[0034] Fig.10 yes Figure 6 A transverse cross-sectional view of the proximal hub portion of the device, Figure 6 Indicated by line 10-10.

[0035] Fig.11 is a state with collapsed constraints set in it Figure 3 An elevation view in partial cross-section of the distal end of a delivery catheter of a device for treating the vasculature of a patient.

[0036] Fig.12 An embodiment of a wire configuration for a device for treating the vasculature of a patient is shown.

[0037] Fig.13A A device for treating the vascular system of a patient is shown, comprising a coil in a proximal region.

[0038] Fig. 13B Shows Fig.13A Top profile of the occlusion device.

[0039] Fig.14 A device for treating a patient's vasculature is shown that includes a coil and a hydrogel in a proximal region.

[0040] Fig.15 The device according to Figures 13-15 is shown deployed within an aneurysm.

[0041] Figures 16A-16C Various configurations of reinforcement elements integrated into the mesh of the device are shown.

[0042] Fig.16D An alternative embodiment is shown that includes additional lines.

[0043] Fig.17 is a schematic diagram of a patient accessed by an introducer sheath releasably secured to the distal end of a delivery device or actuator, a microcatheter, and a device for treating the patient's vasculature.

[0044] Fig.18 is a cross-sectional view of a terminal aneurysm.

[0045] Fig.19 This is a cross-sectional view of an aneurysm.

[0046] Fig. 20 is a schematic cross-sectional view of an aneurysm showing vertical arrows indicating the internal nominal longitudinal and transverse dimensions of the aneurysm.

[0047] Fig.21 yes Fig. 20 A schematic cross-sectional view of an aneurysm of FIG. 1 is shown with a dashed outline of a device for treating a patient's vasculature in a relaxed, unconstrained state, the device extending laterally outside of the aneurysm wall.

[0048] Fig. 22 Is Fig.21 Schematic cross-sectional view of the outline of the device represented by the dashed line in a deployed and partially constrained state within an aneurysm.

[0049] Figure 23-26 A deployment sequence of a device for treating a patient's vasculature is shown.

[0050] Fig. 27 is an elevation view, partially in cross-section, of an embodiment of a device for treating a patient's vasculature deployed within an aneurysm at an oblique angle.

[0051] Fig.28 is an elevation view, partially in cross-section, of an embodiment of a device for treating a patient's vasculature deployed within an irregularly shaped aneurysm.

[0052] Fig.29 A cross-sectional elevational view of a device for treating a patient's vasculature is shown deployed within a vascular defect aneurysm. DETAILED DESCRIPTION

[0053] Discussed herein are devices and methods for treating vascular defects that are suitable for minimally invasive deployment within a patient's vascular system, particularly within a patient's cerebrovascular system. In order to safely and effectively deliver such embodiments to a desired treatment site and effectively deploy them, some device embodiments may be configured to collapse to a low-profile constrained state having lateral dimensions suitable for delivery through the lumen of a microcatheter and deployment from its distal end. Embodiments of these devices may also maintain a clinically effective configuration with sufficient mechanical integrity after deployment to withstand dynamic forces within the patient's vascular system over time that may otherwise cause the deployed device to be compacted. Some device embodiments may also wish to acutely occlude a patient's vascular defect during surgery in order to provide more direct feedback to the attending physician regarding the success of the treatment.

[0054] Intravascular occlusive devices comprising a permeable shell formed from a braided or woven mesh are described in US 2017 / 0095254, US 2016 / 0249934, US 2016 / 0367260, US 2016 / 0249937, and US 2018 / 0000489, all of which are hereby incorporated by reference for all purposes.

[0055] Some embodiments are particularly useful for treating cerebral aneurysms by remodeling the vessel wall so as to completely or partially isolate the vascular defect from the patient's blood flow. Some embodiments can be configured to be deployed within a vascular defect to facilitate reconstruction, bridging, or both of the vessel wall so as to treat the vascular defect. For some of these embodiments, the permeable shell of the device can be configured to anchor or secure the permeable shell in a clinically beneficial position. For some embodiments, the device can be disposed in whole or in part within the vascular defect so as to anchor or secure the device relative to the vascular structure or defect. The permeable shell can be configured to span the opening, neck, or other portion of the vascular defect so as to isolate the vascular defect or a portion thereof from the patient's nominal vascular system, thereby allowing the defect to heal or otherwise minimize the risk of the defect to the patient's health.

[0056] For some or all embodiments of the devices for treating the vascular system of a patient discussed herein, the permeable shell may be configured to allow some initial perfusion of blood through the permeable shell. The porosity of the permeable shell may be configured to sufficiently isolate the vascular defect to promote healing and isolation of the defect, but allow sufficient initial flow through the permeable shell to reduce or otherwise minimize the mechanical forces exerted on the membrane due to the dynamic flow of blood or other fluids within the vascular system to the device. For some embodiments of the devices for treating the vascular system of a patient, only a portion of the permeable shell that spans the opening or neck of the vascular defect, sometimes referred to as the defect spanning portion, needs to be permeable and / or facilitate thrombosis in the patient's blood flow. For such embodiments, the portion of the device that does not span the opening or neck of the vascular defect can be substantially impermeable or completely permeable, having a pore or opening configuration that is too large to effectively promote thrombosis.

[0057] In general, in some cases it may be desirable to use a hollow, thin-walled device having a permeable shell of an elastic material that can be constrained to a low profile for delivery in a patient. Such a device may also be configured to expand radially outward after the constraint is removed, so that the shell of the device assumes a larger volume and fills or otherwise occludes the vascular defect in which it is deployed. The outward radial expansion of the shell can be used to engage some or all of the inner surfaces of the vascular defect, whereby the mechanical friction between the outer surface of the permeable shell of the device and the inner surface of the vascular defect effectively anchors the device within the vascular defect. Some embodiments of such a device may also be partially or completely mechanically captured within the cavity of the vascular defect, particularly in the case where the narrow neck of the defect has a large internal volume. In order to achieve a low profile and volume for delivery and to be able to have a high volume expansion ratio, some device embodiments include a matrix of braided or woven silks that are coupled together by an interlaced structure to form a self-expanding permeable shell, with a hole or opening pattern between the coupling points or intersections of the silk, the spacing of which is substantially regular and stable, while still allowing conformity and volume constraints.

[0058] As used herein, the terms woven and braided are used interchangeably to refer to any form of interlacing of filaments to form a mesh structure. In textile and other industries, these terms may have different or more specific meanings, depending on the product or application, such as whether the article is made in sheet or cylindrical form. For the purposes of this disclosure, these terms are used interchangeably.

[0059] For some embodiments, three factors may be critical for braided or woven wire occlusion devices for treating the patient's vascular system that can achieve the desired clinical results in the endovascular treatment of cerebral aneurysms. We have found that in order to be used effectively in certain applications, the implant device may need to have sufficient radial stiffness to ensure stability, limited aperture to achieve nearly complete acute (intraoperative) occlusion, and a small enough collapse profile to allow insertion through the lumen of the microcatheter. Devices with radial stiffness below a certain threshold may be unstable and may have a higher risk of embolism in some cases. Larger holes between the crossover points of the wire in the braided or woven structure may not produce thrombosis and occlude vascular defects in acute situations, and therefore may not give the treating physician or health professional such clinical feedback that the flow interruption will result in complete and lasting occlusion of the vascular defect being treated. It may be very necessary to deliver a device for treating the patient's vascular system through a standard microcatheter to allow access through the tortuous cerebral vascular system in a manner that the treating physician is accustomed to. A detailed discussion of radial stiffness, aperture, and necessary collapse profile can be found in US2017 / 0095254, which was previously incorporated herein by reference in its entirety.

[0060] As already discussed, some embodiments of devices for treating a patient's vascular system require sizing the device to approximate (or have some oversizing) the size of the vascular site to fill the vascular site. One might assume that scaling the device to a larger size and using a larger wire would be sufficient for such larger embodiments of the device. However, for the treatment of cerebral aneurysms, the diameter or profile of the radially collapsing device is limited by the size of the catheter that can be effectively navigated within the small and tortuous blood vessels of the brain. In addition, as the device made of a given or fixed number of elastic wires of a given size or thickness is larger, the holes or openings between the connections of the wires are correspondingly larger. In addition, for a given wire size, the bending modulus or stiffness of the wire and therefore the structure decreases as the size of the device increases. The bending modulus can be defined as the ratio of stress to strain. Therefore, if the strain (deflection) is low at a given force, the device can be considered to have a high bending modulus or stiffness. A rigid device can also be said to have low compliance.

[0061] In order to appropriately configure larger sized devices for treating a patient's vasculature, it may be useful to model the forces on the device when the device is deployed to a vascular site or defect, such as a blood vessel or aneurysm, that has a diameter or transverse dimension that is smaller than the nominal diameter or transverse dimension of the device in a relaxed, unconstrained state. As discussed, in some cases it may be advisable to "oversize" the device so that there are residual forces between the outer surface of the device and the inner surface of the vessel wall. The inward radial forces on the device 10 caused by oversizing are Figure 1The arrow 12 in the figure representing the radial force inward is schematically shown. Figure 2 As shown, Figure 1 These compressive forces on the wire 14 of the device can be modeled as a simply supported beam 16 with a distributed load or force, as shown by arrows 18 in the figure. From the following formula, it can be seen that for the deflection of a beam with two simple supports 20 and a distributed load, the deflection is a function of the fourth power of the length L:

[0062] Beam deflection = 5FL 4 / 384El

[0063] Where F = force,

[0064] L = length of beam,

[0065] E = Young's modulus, and

[0066] l = moment of inertia.

[0067] Thus, compliance increases significantly as the device size increases and L increases. Thus, when inserted into a vascular site, such as a vessel or aneurysm, the outward radial force exerted by the outer surface of the wire 14 of the device 10 against the restraining force is low for a given amount of device compression or oversizing. Such forces may be important in certain applications to ensure device stability and reduce the risk of device migration and potential distal embolization.

[0068] In some embodiments, a combination of small and large wire sizes can be utilized to create a device having a desired radial compliance and also having a collapsed profile configured to fit through the lumen of a commonly used microcatheter. Even a device made with a small number of larger wires 14 will provide reduced radial compliance (or increased stiffness) compared to a device made with all small wires. Due to the change in moment of inertia resulting from an increase in diameter, even a small number of larger wires can provide a significant increase in bending stiffness without increasing the total cross-sectional area of ​​the wire. The moment of inertia (I) of a round wire or wire can be defined by the following formula:

[0069] I = πd 4 / 64

[0070] Where d is the diameter of the wire or filament.

[0071] Since the moment of inertia is a function of the fourth power of the wire diameter, a small change in diameter can greatly increase the moment of inertia. Therefore, a small change in wire size can have a significant effect on the deflection at a given load, and thus on the compliance of the device.

[0072] Thus, stiffness can be significantly increased without a large increase in the cross-sectional area of ​​the collapsed profile of the device 10. This may be particularly important as device embodiments are made larger to treat large aneurysms. While large brain aneurysms may be rare, they present a significant treatment challenge as some of the embolization devices currently available to physicians have poor results compared to smaller aneurysms.

[0073] Thus, some embodiments of devices for treating a patient's vascular system can be formed using a combination of wires 14 having a plurality of different diameters, such as 2, 3, 4, 5 or more different diameters or transverse dimensions. In device embodiments using wires having two different diameters, some larger wire embodiments may have a transverse dimension of about 0.001 inch to about 0.004 inch, and some small wire embodiments may have a transverse dimension or diameter of about 0.0004 inch and about 0.0015 inch, more specifically, about 0.0004 inch to about 0.001 inch. The ratio of the number of large wires to the number of small wires can be between about 2 and 12, or between about 4 and 8. In some embodiments, the difference in diameter or transverse dimension between the larger and smaller wires can be less than about 0.004 inch, more specifically, less than about 0.0035 inch, and even more specifically, less than about 0.002 inch.

[0074] As described above, the device embodiment 10 for treating the vascular system of a patient may include a plurality of wires, fibers, yarns, tubes or other filamentary elements forming a structure used as a permeable shell. For some embodiments, a spherical shape may be formed by such a silk by connecting or fixing the ends of a tubular braided structure. For such embodiments, the density of the woven or braided structure may be inherently increased at or near the ends where the wires or silks 14 are gathered together, and reduced at or near the middle portion 30 arranged between the proximal end 32 and the distal end 34 of the permeable shell 40. For some embodiments, the ends or any other suitable parts of the permeable shell 40 may be positioned in the opening or neck of a vascular defect such as an aneurysm for treatment. Therefore, a woven or braided filamentary device with a permeable shell may not need to add a separate defect spanning structure having properties different from the nominal portion of the permeable shell to achieve hemostasis and occlusion of a vascular defect. Such a silk device may be manufactured by braiding, weaving or other suitable silk manufacturing techniques. Such device embodiments may be shaped to various three-dimensional shapes, such as discussed herein.

[0075] Reference Figure 3-10 , shows an embodiment of a device for treating a patient's vascular system 10. The device 10 includes a self-expanding elastic permeable shell 40 having a proximal end 32, a distal end 34, a longitudinal axis 46, and also includes a plurality of elongated elastic filaments 14, the elongated elastic filaments 14 including at least two different transverse sizes of large filaments 48 and small filaments 50, such as Figure 5, 7 18. The wires 14 have a braided structure and are fixed relative to each other at their proximal ends 60 and distal ends 62. The permeable shell 40 of the device has a radially constrained elongated state, which is configured for delivery within a microcatheter 61, such as Fig.11 As shown, the fine braided wires 14 extend longitudinally from a proximal end 42 to a distal end 44 radially adjacent to one another along the length of the wires.

[0076] like Figure 3-6 As shown, the permeable shell 40 also has an expanded relaxed state with a spherical and longitudinally shortened configuration relative to the radially constrained state. In the expanded state, the braided wires 14 form a self-expanding elastic permeable shell 40 in a smooth path that expands radially from the longitudinal axis 46 of the device between the proximal end 32 and the distal end 34. The braided structure of the wires 14 includes a plurality of openings 64 formed in the permeable shell 40 between the braided wires. For some embodiments, the largest opening in the openings 64 can be configured to only allow blood to flow through the opening at a speed below the thrombosis threshold speed. The thrombosis threshold speed is defined by at least some people as the time-averaged speed at which more than 50% of the surface of the vascular graft is covered with thrombus when deployed in the patient's vascular system. In the case of aneurysm occlusion, a slightly different threshold may be appropriate. Therefore, the thrombosis threshold speed used herein should include the speed at which coagulation occurs in or on a device (e.g., device 10) deployed in the patient's vascular system, so that blood flow into the vascular defect treated by the device is substantially blocked during the treatment process for more than about 1 hour or other time. In some cases, after a sufficient amount of contrast medium is injected into the patient's vascular system upstream of the implant site and visualized as it dissipates from the site, a small amount of contrast medium that enters the vascular defect may indicate an obstruction of blood flow into the vascular defect. Such flow obstruction that persists in less than about 1 hour or during the implantation procedure may also be referred to as acute occlusion of the vascular defect.

[0077] In this way, once the device 10 is deployed, any blood flowing through the permeable shell can be slowed to a rate below the threshold rate for thrombosis, and thrombi will begin to form on and around the openings in the permeable shell 40. Ultimately, the process can be configured to produce an acute occlusion of the vascular defect in which the device 10 is deployed. For some embodiments, at least the distal end of the permeable shell 40 can have a reverse bend in an everted configuration such that the fixed distal end 62 of the wire 14 is axially retracted within the nominal permeable shell structure or profile in the expanded state. For some embodiments, the proximal end of the permeable shell also includes a reverse bend in an everted configuration such that the fixed proximal end 60 of the wire 14 is axially retracted within the nominal permeable shell structure 40 in the expanded state. As used herein, the term eversion can include, for example, Figure 3-6The device embodiment shown in FIG. 1 has a reverse curved everted, partially everted and / or concave structure. For such an embodiment, the ends 60 and 62 of the wire 14 of the permeable shell or hub structure disposed around the ends can be retracted within or below the spherical periphery of the permeable shell of the device.

[0078] The elongated resilient filaments 14 of the permeable shell 40 may be secured relative to one another at their proximal and distal ends 60, 62 by one or more methods, including welding, soldering, adhesive bonding, epoxy bonding, and the like. In addition to securing the ends of the filaments together, a distal hub 66 may be secured to the distal ends 62 of the filaments 14 of the permeable shell 40 and a proximal hub 68 may be secured to the proximal ends 60 of the filaments 14 of the permeable shell 40. The proximal hub 68 may include a cylindrical member that extends proximally beyond the proximal ends 60 of the filaments to form a cavity 70 within a proximal portion of the proximal hub 68. The proximal cavity 70 may be used to retain an adhesive, such as epoxy, solder, or any other suitable bonding agent, to secure an elongated breakaway tether 72, which in turn may be detachably secured to a distal hub 66 such as a proximal hub 68. Fig.11 The delivery device shown.

[0079] For some embodiments, the elongated elastic wire 14 of the permeable shell 40 can have a generally circular cross-section and be made of a superelastic material, which can also be a shape memory metal. The shape memory metal of the wire of the permeable shell 40 can be heat set in a spherical configuration in a relaxed expanded state, such as Figure 3-6 Suitable superelastic shape memory metals may include alloys such as NiTi alloys, etc. The superelastic properties of such alloys may be used to provide elastic properties to the filaments 14 so that they may be heat set into the spherical form shown, fully constrained for delivery within the lumen of a microcatheter, and then released to self-expand back to the substantially original heat set shape of the spherical configuration when deployed within a patient.

[0080] The device 10 can have an everted filamentary structure having a permeable shell 40 having a proximal end 32 and a distal end 34 in an expanded relaxed state. For the illustrated embodiment, the permeable shell 40 has a substantially closed configuration. Some or all of the permeable shell 40 of the device 10 can be configured to substantially block or prevent fluid flow or pressure from entering a vascular defect or otherwise isolate a vascular defect for a period of time after the device is deployed in an expanded state. The permeable shell 40 and the device 10 also generally have a low profile, radially constrained state, such as Fig.11 As shown, it has an elongated tubular or cylindrical configuration including a proximal end 32, a distal end 34 and a longitudinal axis 46. When in a radially constrained state, the elongated flexible filaments 14 of the permeable shell 40 can be arranged substantially parallel and in close lateral proximity to each other between the proximal and distal ends, forming a substantially tubular or compressed cylindrical structure.

[0081] The proximal ends 60 of at least some of the filaments 14 of the permeable shell 40 can be fixed to the proximal hub 68, and the distal ends 62 of at least some of the filaments 14 of the permeable shell 40 can be fixed to the distal hub 66, and the proximal hub 68 and the distal hub 66 are arranged to be substantially concentric with the longitudinal axis 46, such as Figure 4 The ends of the wire 14 can be secured to the respective hubs 66 and 68 by any of the methods discussed above with respect to securing the ends of the wires to one another, including the use of adhesives, solder, welding, etc. The intermediate portion 30 of the permeable shell 40 can have a first transverse dimension having a low profile suitable for delivery from a microcatheter, such as Fig.11 The radial constraint on the device 10 may be applied by the inner surface of the lumen of the microcatheter, such as the distal portion of the microcatheter 61 shown, or it may be applied by any other suitable mechanism that can be released in a controlled manner when the device 10 is ejected from the distal end of the catheter. Fig.11 , the proximal end or hub 68 of the device 10 is secured to the distal end of an elongated delivery device 111 of a delivery system 112 disposed at the proximal hub 68 of the device 10. Further details of the delivery device can be found, for example, in US 2016 / 0367260, which was previously incorporated herein by reference in its entirety.

[0082] Some device embodiments 10 having a woven or braided wire structure can be formed using about 10 to about 300 wires 14, more specifically, about 10 to about 100 wires 14, and even more specifically, about 60 to about 80 wires 14. Some embodiments of the permeable shell 40 may include about 70 to about 300 wires extending from the proximal end 32 to the distal end 34, more specifically, about 100 to about 200 wires extending from the proximal end 32 to the distal end 34. For some embodiments, the wire 14 may have a transverse dimension or diameter of about 0.0008 inches to about 0.004 inches. In some cases, the outer transverse dimension or diameter of the elongated elastic wire 14 can be about 0.0005 inches to about 0.005 inches, more specifically, about 0.001 inches to about 0.003 inches, and in some cases about 0.0004 inches to about 0.002 inches. For some device embodiments 10 comprising different-sized silk 14, the large silk 48 of permeable shell 40 can have a transverse dimension or diameter of about 0.001 inch to about 0.004 inch and the transverse dimension or diameter of small silk 50 can be about 0.0004 inch to about 0.0015 inch, more specifically, about 0.0004 inch to about 0.001 inch. In addition, the transverse dimension between small silk 50 and large silk 48 or the difference of diameter can be less than about 0.004 inch, more specifically, less than about 0.0035 inch, even more specifically, less than about 0.002 inch. For the embodiment of the permeable shell 40 comprising different-sized silk 14, the number of the small filaments 50 of permeable shell 40 can be about 2 to 1 to about 15 to 1 relative to the number of the large filaments 48 of permeable shell 40, more specifically, about 2 to 1 to about 12 to 1, even more specifically, about 4 to 1 to about 8 to 1.

[0083] The expanded relaxed state of the permeable shell 40, such as Figure 4 As shown, the configuration with axial shortening relative to the constrained state is such that the proximal hub 68 is disposed closer to the distal hub 66 than in the constrained state. Both hubs 66 and 68 are disposed substantially concentrically with the longitudinal axis 46 of the device, and each filamentary element 14 forms a smooth arc between the proximal hub 66 and the distal hub 68, with a reverse bend at each end. For some embodiments, the longitudinal spacing between the proximal hub 66 and the distal hub 68 of the permeable shell 40 in the expanded relaxed state can be about 25% to about 75% of the longitudinal spacing between the proximal hub 66 and the distal hub 68 in the restricted cylindrical state. The arc of the wire 14 between the proximal end 32 and the distal end 34 can be configured such that the middle portion of each wire 14 has a second transverse dimension that is substantially larger than the first transverse dimension.

[0084] For some embodiments, the permeable shell 40 may have a first transverse dimension in a collapsed radially constrained state of about 0.2 mm to about 2 mm and a second transverse dimension in a relaxed expanded state of about 4 mm to about 30 mm. For some embodiments, the second transverse dimension of the permeable shell 40 in the expanded state may be about 2 times to about 150 times the first transverse dimension, more specifically, about 10 times to about 25 times the first or constrained transverse dimension. The longitudinal spacing between the proximal end 32 and the distal end 34 of the permeable shell 40 in the relaxed expanded state may be about 25% to about 75% of the spacing between the proximal end 32 and the distal end 34 in the constrained cylindrical state. For some embodiments, the major transverse dimension of the permeable shell 40 in the relaxed expanded state may be about 4 mm to about 30 mm, more specifically, about 9 mm to about 15 mm, and even more specifically, about 4 mm to about 8 mm.

[0085] The arcuate portion of the wire 14 of the permeable shell 40 may have a sinusoidal shape having a first or outer radius 88 and a second or inner radius 90 near the end of the permeable shell 40, such as Figure 6 As shown. This sinusoidal or multi-curve shape can provide concavity in the proximal end 32, which can reduce flow obstruction in the parent vessel adjacent to the vascular defect. For some embodiments, the first radius 88 and the second radius 90 of the permeable shell 40 can be between about 0.12 mm and about 3 mm. For some embodiments, the distance between the proximal end 32 and the distal end 34 can be less than about 60% of the total length of the permeable shell 40. When the device 10 encounters resistance at the distal end 34, this configuration allows the distal end 34 to bend downward toward the proximal end 32, and thus can provide longitudinal conformity. In some embodiments, the wire 14 can be shaped so that there is no portion without curvature over a distance exceeding about 2 mm. Therefore, for some embodiments, each wire 14 can have a substantially continuous curvature. This substantially continuous curvature can provide smooth deployment and can reduce the risk of vascular perforation. For some embodiments, one of the ends 32 or 34 can be retracted or everted to a greater extent than the other so as to be more conformable in the longitudinal or axial direction than the other end.

[0086] For some embodiments, the first radius 88 and the second radius 90 of the permeable shell 40 can be between about 0.12 mm and about 3 mm. For some embodiments, the distance between the proximal end 32 and the distal end 34 can be greater than about 60% of the total length of the expanded permeable shell 40. Therefore, the maximum longitudinal distance between the inner surfaces can be about 60% to about 90% of the longitudinal length of the outer surface or the total length of the device 10. When the device 10 encounters resistance at the distal end, the gap between the hubs 66 and 68 at the proximal end 32 and the distal end 34 can allow the distal hub 66 to bend downward toward the proximal hub 68 and thus provide longitudinal compliance. The wire 14 can be shaped so that there is no portion without curvature over a distance exceeding about 2 mm. Therefore, for some embodiments, each wire 14 can have a substantially continuous curvature. This substantially continuous curvature can provide smooth deployment and can reduce the risk of vascular perforation. The distal end 34 can be retracted or everted to a greater extent than the proximal end 32, so that the distal portion of the permeable shell 40 can be more conformable in the radial direction than the proximal portion. The compliance of the distal portion can provide better device compliance for irregularly shaped aneurysms or other vascular defects. The convex surface of the device can be bent inward to form a concave surface to conform to the curvature of the vascular site.

[0087] Fig.10 An enlarged view of the wire 14 disposed within the proximal hub 68 of the device 10 is shown, wherein two different sizes of wire 14 are constrained and tightly packed by the outer ring of the proximal hub 68. A tether member 72 may optionally be disposed within the middle portion of the wire 14 or within the lumen 70 of the proximal hub 68 proximal to the proximal end 60 of the wire 14, as shown in FIG. Figure 6 The distal end of the tether 72 can be secured with a knot 92 formed in its distal end that is mechanically captured in the cavity 70 of the proximal hub 68 formed by the proximal shoulder 94 of the proximal hub 68. The knotted distal end 92 of the tether 72 can also be secured by bonding or potting the distal end of the tether 72 within the cavity 70 and optionally between the proximal ends 60 of the wires 14 with mechanical compression, adhesive bonding, welding, soldering, brazing, etc., or the like. Figure 6 The illustrated tether embodiment 72 has a knotted distal end 92 that is encapsulated with an adhesive in the lumen of the proximal hub 68. Such a tether 72 may be a dissolvable, detachable, or releasable tether that may be part of a delivery device 111 for deploying the device 10, such as Fig.11 and Figure 23-26 shown. Fig.10 Also shown are the large wire 48 and the small wire 50 disposed within and constrained by the proximal hub 68 , which may be configured to secure the large wire 48 and the small wire 50 in position relative to each other within an outer ring of the proximal hub 68 .

[0088] Figure 7 and 8Some embodiments of configurations of braided wires 14 of a permeable shell 40 of a device 10 for treating a patient's vascular system are shown. The braided structure in each embodiment is shown as having circular shapes 100 disposed within the pores 64 of a woven or braided structure, wherein the circular shapes 100 are in contact with each adjacent wire segment. The pore opening size can be determined at least in part by the size of the wire elements 14 of the braid, the angles formed by the overlapping wires relative to each other, and the number of picks per inch of the braid structure. For some embodiments, the cell or opening 64 can have a size such as Figure 7 The elongated, substantially diamond-shaped shape shown, and the aperture or opening 64 of the permeable shell 40 may have a substantially more square shape toward the middle portion 30 of the device 10, such as Figure 8 As shown. The length of the diamond-shaped holes or openings 64 can be significantly greater than the width, especially near the hubs 66 and 68. In some embodiments, the ratio of the length to the width of the diamond-shaped holes or openings can exceed 3 to 1 for some cells. The diamond-shaped openings 64 can have a length greater than the width, and thus have an aspect ratio defined as length / width greater than 1. The openings 64 near the hubs 66 and 68 can have a much larger aspect ratio than the openings 64 farther from the hubs, such as Figure 7 The aspect ratio of the openings 64 adjacent to the hub may be greater than about 4 to 1. For some embodiments, the aspect ratio of the openings 64 near the maximum diameter may be between about 0.75 to 1 and about 2 to 1. For some embodiments, the aspect ratio of the openings 64 in the permeable shell 40 may be about 0.5 to 1 to about 2 to 1.

[0089] For some embodiments, the size of the aperture defined by the largest circular shape 100 that can be arranged within the opening 64 of the braided structure of the permeable shell 40 without displacing or distorting the wire 14 around the opening 64 can range from about 0.005 inches to about 0.01 inches, more specifically, about 0.006 inches to about 0.009 inches, and even more specifically, about 0.007 inches to about 0.008 inches. In addition, at least some of the openings 64 formed between adjacent wires 14 of the permeable shell 40 of the device 10 can be configured to only allow blood to flow through the openings 64 at a speed below the thrombosis threshold speed. For some embodiments, the largest opening 64 in the permeable shell structure 40 can be configured to only allow blood to flow through the openings 64 at a speed below the thrombosis threshold speed. As described above, for some embodiments, the aperture can be less than about 0.016 inches, more specifically, less than about 0.012 inches. For some embodiments, the openings 64 formed between adjacent wires 14 can be about 0.005 inches to about 0.04 inches.

[0090] Fig.12The embodiment of the proximal hub 68 is shown in cross section, showing the configuration of the silk, which can be closely packed and radially constrained by the inner surface of the proximal hub 68. In some embodiments, the woven or braided structure of the permeable shell 40 formed by this silk 14 can be composed of a large number of small silks. The number of silk 14 can be greater than 125 and can also be between about 80 silks and about 180 silks. As mentioned above, the total number of the silk 14 of some embodiments can be about 70 silks to about 300 silks, more specifically, about 100 silks to about 200 silks. In some embodiments, the braided structure of the permeable shell 40 can be composed of two or more sizes of silk 14. For example, the structure can have several large silks and several small silks that provide structural support, and the small silk provides required pore size and density and thereby provides the flow resistance reaching the thrombus threshold speed in some cases. For some embodiments, the transverse dimension or diameter of the small filaments 50 of the permeable shell 40 may be about 0.0006 inches to about 0.002 inches in some embodiments, and about 0.0004 inches to about 0.001 inches in other embodiments. The transverse dimension or diameter of the large filaments 48 may be about 0.0015 inches to about 0.004 inches in some embodiments and about 0.001 inches to about 0.004 inches in other embodiments. The filaments 14 may be woven into a plain weave, i.e., a one-over-one structure (e.g., Figure 7 and 8 shown) or supplementary weave; more than one warp thread is interwoven with one or more weft threads. The pick count may vary from about 25 to 200 picks per inch (PPI).

[0091] In order to properly treat an aneurysm, correct positioning of the intravascular device is important, especially with respect to placement over the neck of the aneurysm. The neck area is where blood flows into the aneurysm, so correct positioning relative to the neck is important. In addition, the proximal stability of the intravascular device is important to prevent the device from compacting or otherwise moving into the aneurysm. The following embodiments address these issues by utilizing proximal reinforcement or stiffening elements (e.g., coils or springs) to enhance the proximal stiffness of the device.

[0092] Fig.13A and 13B An embodiment of a device 110 is shown that includes a permeable shell 140 for treating a vascular defect, such as an aneurysm 160. The device also includes reinforcing or stiffening elements 122 incorporated into a proximal portion 133 of the permeable shell 140. In some embodiments, these reinforcing or stiffening elements 122 are helical coils wrapped around a portion of the wire of the device 110.

[0093] like Fig.15As shown, the proximal portion 133 is intended to be located at or proximate to the neck of the aneurysm 160, while the remainder of the permeable shell 140 fills the space distal to the neck of the aneurysm 160. As previously described, it is desirable to increase the stiffness at the proximal region 133 of the device 110 to facilitate proper positioning of the device 110 within the aneurysm. Fig.13A and 13B As shown, the inclusion of a coiled wire reinforcing element 122 in the proximal portion of the device is one way to increase stiffness in the proximal portion 133. As described in other embodiments, the occluding device itself is formed of one or more braided wires that are joined or gathered with hubs or marker bands 66, 68 at the proximal and distal ends of the device 110. The coiled wire reinforcing element 122 can be wrapped around various portions of the constituent braided wires or filaments 114 of the occluding device, in other words, the coiled wire element is wrapped directly around the filaments 114 of the device itself.

[0094] The reinforcing or strengthening element 122 can be made of a variety of materials, for example, a shape memory metal material such as Nitinol or stainless steel. Alternatively, a radiopaque material such as platinum, a platinum alloy (e.g., platinum-tungsten), palladium, gold, or tantalum can be used, one advantage of which is increased visibility of the proximal region of the device so the physician can better see how the proximal end is positioned relative to the neck of the aneurysm. Composite materials such as DFT (stretch-filled tube) wires can also be used. These DFT materials can include a radiopaque (e.g., tantalum or platinum) core surrounded by a shape memory (e.g., Nitinol) sheath to provide greater visualization as well as shape memory properties.

[0095] Because these reinforcing elements 122 (e.g., coils or springs) are used to enhance the proximal stiffness of the device 110, the coiled elements 122 can have their own stiffness values ​​and force values ​​(as a function of stiffness). The coiled elements have material properties similar to springs, and the "k" value of the spring represents its stiffness. This k value is represented by the following equation: k = Gd 4 / (8nD 3 ), where the variables include G (modulus of stiffness of the material), d (wire diameter of the wire forming the coil or spring), n (number of coils), and D (diameter of the entire coil). Generally, for two similarly designed materials, any change in diameter will produce an approximately 4th power exponential difference in the associated stiffness. Thus, for example, the materials comprising the coiled element, the wire diameter of the coiled element, and the overall coil diameter can be tailored to facilitate a desired diameter profile. In some examples, the diameter of the coiled element 122 can be 1-3 times the diameter of the wire braid and the associated stiffness is approximately 1-81, 1.2-50, 1.25-25, or 1.5-6 times that of the rest of the device 110.

[0096] In some embodiments, the reinforcing elements 122 are helically configured as a consistent coil (similar to multiple nested windings forming a consistent two-dimensional coiled shape). In some embodiments, the coiled elements 122 are individually wound into shape memory heat set complex three-dimensional shapes. Such three-dimensional shaped coils are described in U.S. Patent Nos. 6,605,101, 8,066,036, and 9,533,344, all of which are incorporated herein by reference in their entirety for all purposes.

[0097] The length of the proximal portion 133 of the permeable shell 140 can be about 1 / 3, or about 1 / 4, of the length of the permeable shell 140 in the expanded state. The proximal portion 133 of the permeable shell 140 can include a portion starting at the proximal side 132 and extending to about 20% or less, or about 25% or less, or about 30% or less, or about 33% or less, or about 40% or less of the total length of the device 110 in the expanded state. The proximal portion 133 of the permeable shell 140 can include a portion starting at the proximal side 132 and extending to between about 10% and about 40% of the total length of the device 110 in the expanded state, or between about 10% and about 30%, or between about 15% and about 40%, or between about 20% and about 40%. The coiled element may be incorporated into at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least 90%, or at least about 100% of the proximal portion. The coiled element 122 may be incorporated into between about 20% and about 90%, or between about 30% and 80%, or between about 40% and 70%, or between about 50% and 80%, or between about 30% and 90% of the proximal portion.

[0098] The proximal portion 133 (which utilizes the reinforcing or stiffening element 122) may include at least about one coil, or at least about 2 coils, or at least about 3 coils, or at least about 4 coils, or at least about 5 coils, or at least about 6 coils, or at least about 7 coils, or at least about 8 coils, or at least about 9 coils, or at least about 10 coils. The number of coils that the proximal portion may include is between about 2 and about 10, or between about 3 and about 12, or between about 4 and about 8, or between about 5 and about 10, or between about 5 and about 15.

[0099] Fig. 13B A top view of an occlusive device including a coiled reinforcing element 122 is shown. The coiled element can be added to the braid in a variety of patterns. For example, the coiled element 122 can be incorporated into the entire proximal portion 133 of the braid. The coiled element is similar to a micro spring and is attached to the hub or marker band (see Figure 6The coiled reinforcement element 122 may be placed over the constituent wires comprising the braid, for example directly over one or more wire portions of the braid. Figures 16A-16C Various configurations are shown for how the coiled reinforcing element 122 may be integrated into the braid or mesh of the occlusive device. Fig.16A In the embodiment of the present invention, the coiled reinforcing element 122 is located (in a 1:1 relationship) on, disposed about, adjacent to, or otherwise associated with at least a portion of one of the constituent threads or strands 114 that make up the mesh of the device 110. In this configuration, different constituent strands of the mesh can utilize their own different coiled reinforcing elements 122. Fig. 16B An alternative configuration is shown whereby each coiled reinforcing element 122 is located above, around, adjacent to, or otherwise associated with a plurality of constituent wire or filament 114 elements forming the braid. Fig. 16C , each coiled reinforcement element 122 is located above, disposed about, adjacent to, or otherwise associated with two or more filament 114 elements forming the braid, however they are placed between the various filament intersections and are therefore spaced apart to a greater degree.

[0100] The reinforcing element 122 may be secured to the wire braid of the device 110 in a variety of ways. For example, at the hub or marker bands 66, 68 (e.g., Figure 6 ) is assembled on both sides of the device (before all ends of the device are secured, meaning that the ends of the device 110 are open) so that the reinforcing element 122 can be placed on the wires or threads of the device 110), and the coiled element is placed on one or more of the constituent threads of the mesh or braid of the device 110 (see, for example, Figures 16A-16C ). In one embodiment, these coiled reinforcement elements 122 are free floating and not directly secured to the wires of the device braid. In one embodiment, the coil elements 122 may be free floating at one end and secured at one end, or may be secured at both ends by epoxy or UV glue, or in some cases, may be laser welded to the original braid wire.

[0101] The coiled reinforcing elements 122 may be added to all of the constituent wires of the proximal portion of the device braid 110, only some of the constituent wires, or some along the proximal portion of the device 110 in a sheet-like manner, etc. The placement of the coiled reinforcing elements 122 will affect the stiffness of the device and may be customized based on the size of the occluding device, the neck area of ​​the treatment site (e.g., an aneurysm), the overall treatment site size, and the area of ​​the body being treated.

[0102] Alternative ways of enhancing stiffness at the proximal end of the device may also be used. For example, the number of wires and the size of the wires in the proximal portion of the device may vary to increase stiffness along that region compared to the rest of the device, i.e., the proximal region may use larger wires or a different number of wires in its constituent braids than the rest of the device, which may not require the addition of a separate reinforcing element 122 to increase stiffness. In addition, a stiffer, radiopaque material (e.g., tantalum or stretched fill tube (DFT)) may also be used as part of the braid in the proximal portion of the device to increase stiffness and visualization. In some embodiments, additional wires may be wrapped around or adjacent to the constituent wires / filaments of the proximal portion of the device 110 braid to selectively enhance that region. For example, additional wires or additional braids may be wrapped around each other within the proximal device braid to increase stiffness in that region. Fig.16D An arrangement is shown that is intended to represent the proximal portion of the device 110. The thinner wires 114 represent the device braid, while the thicker wires 114 represent one or more separate wires placed near the constituent wires or filaments of the braid to selectively reinforce that area. These reinforcing wires can be thicker, thinner, or the same as the rest of the wire braid, and can be selectively connected to portions of the wire braid to increase stiffness, or not connected and simply be a portion of the wider braid that defines the proximal end of the device 110. As shown in FIG. Fig.16D As shown, the additional wires 214 effectively reduce the porosity or pore space of the cross-section shown and increase the associated braid density of the additional wires, thereby providing increased resistance to blood flow while increasing stiffness due to the additional material.

[0103] The permeable shell 140 is primarily made of wires including a strong shape memory metal material such as Nitinol. The permeable shell 140 can be made of wires having a smaller diameter than a device without the coiled element 122. The permeable shell can include about 36 to 72 wires, or about 72 to 108 wires, or about 108 to 144 wires. The diameter of the wire can be between about 0.001" and 0.004", or between about 0.004" and 0.0015", or between about 0.0004" and 0.001". The permeable shell 140 can also have wires of different diameters. The permeable shell can be made of wires having two different diameters, or three different diameters, or four different diameters, or five different diameters. The permeable shell can also have wires made of different materials. For example, the permeable shell can include wires made of Nitinol, and can also include composite (DFT) wires.

[0104] As described above, the permeable shell and proximal portion of the intravascular device 110 have different axial stiffnesses because the proximal portion is configured to be stiffer (through the various embodiments described). For example, the proximal portion of the intravascular device 110 is 1.0 to 3 times stiffer in radial and / or axial stiffness.

[0105] The proximal portion 133 of the device 110 is stiffer (and has a more occlusive effect, as described above) due to the reinforcing elements 122 than the distal portion 135 of the device 110 (which lacks these reinforcing elements 122), as described above. Fig.13A As shown. The distal portion 135 can be soft and deformable. Therefore, the distal portion 135 maintains greater flexibility, making it easier to adopt the shape of the target area (e.g., aneurysm 160). The soft distal end 134 and distal region 135 will allow the device 110 to conform to different shapes of aneurysms and substantially fill the annular sac (the inner cavity of the aneurysm). In some embodiments, the soft distal end 134 and distal region 135 will also allow the manufacture of fewer and more types of implant devices 110 with different heights, because one device 110 will be able to be used for one aneurysm diameter size but a range of aneurysm heights, thereby reducing manufacturing costs. For example, a device 110 with an expanded height of 8 mm can be suitable for aneurysms with a height between about 4 mm and about 8 mm. The distal portion of the permeable shell may have a smaller or lower radial stiffness, for example, about 1 / 3 to about 1 / 2 of the stiffness of the proximal portion of the intravascular device 110.

[0106] In addition, due to the increased stiffness of the proximal region 133, there is also a greater anchoring force along the proximal region 133, which helps to seal the neck region and anchor the occluding device 110 in place. This reduces the risk of the occluding device being dislodged from the neck of the treatment location and repositioned into the aneurysm sac. The improved anchoring at the neck of the aneurysm allows for universal sizing, as the rest of the intravascular device 110 can be as soft as possible to fill the volume space of the aneurysm sac. The intravascular device 110 with a soft distal end also has the additional benefit of improved safety during deployment.

[0107] In an alternative embodiment, if Fig.14As shown, a hydrogel may be included in the coil 124 to further increase the occlusion along the proximal portion of the device. Hydrogels are sometimes used in other embolic devices (e.g., embolic coils for occluding target structures) and are configured to expand when reacting with blood (typically reacting with the pH or aqueous components of the blood), thereby enhancing the occlusion or space filling effect of the device. The coiled elements along the proximal side of the device may include a hydrogel component that expands when placed on the treatment site, thereby enhancing the occlusive effect of the proximal portion of the device. For example, the hydrogel may be coated around the winding wire containing the coil, meaning that the hydrogel extends radially from the surface of the wire when expanded. Alternatively, one or more portions of the winding configuration forming the coil nested loops may utilize a hydrogel (i.e., the hydrogel is placed within the lumen of the coil), which configuration is described in more detail in U.S. Patent No. 8,377,091, which is incorporated herein by reference in its entirety. Alternative hydrogel configurations may utilize a hydrogel selectively placed along the proximal braided structure comprising the occlusive device, for example, coated or fixed on a specific wire component of the braid or attached to the proximal portion of the braid. In one embodiment, the hydrogel filaments may be inserted into micro-springs assembled on the proximal region of the intravascular device 110. Alternatively, the hydrogel may be shaped into a reinforcing element (e.g., a spring or coil) and wrapped around the wires at the proximal end of the device.

[0108] The use of coiled elements 122, 124, along with increasing the stiffness of the proximal portion, will also increase occlusion along the proximal portion because the coiled elements will increase the total line thickness along the proximal portion. In other words, the greater wire coverage will create a more closed barrier to blood flow, thereby also increasing occlusion along the proximal portion of the device. Similarly, for the coiled element 124, the hydrogel is a biocompatible material that promotes re-endothelialization and will increase endothelial growth on the neck of the aneurysm, which will ultimately occlude the aneurysm. In addition, the expanded state of the hydrogel will provide increased resistance to blood flow in the proximal portion of the device 110.

[0109] The use of reinforcing elements 122, 124, whether configured as coils, springs, additional braided wires, or otherwise, effectively increases the stiffness and braid density of the proximal region of the device 110. Since the additional reinforcing elements 122, 124 take up more space along the device 110, these elements also serve to reduce the porosity or "open space" formed between the wire intersections in the proximal portion of the device.

[0110] Some intravascular device embodiments may include proximal and distal grooves (see, e.g., Figure 6, which uses proximal and distal recesses or grooves at the ends of the braid). The proximal recess will be configured to primarily abut the neck of the aneurysm, with the line including the edge of the recess, groove, or concave portion disrupting blood flow into the aneurysm. With respect to the embodiments presented above, reinforcing elements 122 can be placed at least along this proximal dimple or depression area to further disrupt blood flow into the aneurysm (e.g., the reinforcing elements 122 will thicken this area, presenting more of an entry blood barrier). These reinforcing elements 122 will also increase the stiffness of this proximal area, where the reinforcing elements 122 can continue into the rest of the proximal portion of the braid (e.g., see FIG. 13 ) to increase stiffness along a larger proximal portion of the braid.

[0111] In other embodiments, the concepts presented herein can be used to increase stiffness or flow disruption along a larger portion of the occluding device. For example, in a large aneurysm with a particularly wide neck, it may be necessary to increase stiffness along a significant portion or even the entire occluding device 110 to hold the device in place. Thus, a larger portion of the device 110 can utilize reinforcement structures 122, 124.

[0112] For some embodiments, the permeable shell 40, 140 or portions thereof may be porous and may be highly liquid permeable. Typically having a flow rate of less than 2000 ml / min / cm2 when measured at a pressure of 120 mmHg. 2 Compared to most vascular prosthetic fabrics or grafts, the permeable shell 40 of some embodiments discussed herein may have a water permeability greater than about 2000 ml / min / cm 2 Water permeability, in some cases greater than about 2500 ml / min / cm 2 For some embodiments, the water permeability of permeable shell 40 or a portion thereof may be between about 2,000 and 10,000 ml / min / cm2 when measured at a pressure of 120 mmHg. 2 More specifically, about 2000 ml / min / cm 2 To about 15000 ml / min / cm 2 .

[0113] Device embodiments and their components may include metals, polymers, biomaterials, and composites thereof. Suitable metals include zirconium-based alloys, cobalt-chromium alloys, nickel-titanium alloys, platinum, tantalum, stainless steel, titanium, gold, and tungsten. Possibly suitable polymers include, but are not limited to, acrylics, silk, silicones, polyvinyl alcohol, polypropylene, polyvinyl alcohol, polyesters (e.g., polyethylene terephthalate or PET), polyetheretherketone (PEEK), polytetrafluoroethylene (PTFE), polycarbonate polyurethane (PCU), and polyurethane (PU). Device embodiments may include materials that degrade or are absorbed or eroded by the body. Bioabsorbable (e.g., decomposed and absorbed by cells, tissues, or other mechanisms in the body) or bioresorbable (similar to bioresorbable) materials may be used. Alternatively, biodegradable (e.g., eroded or degraded over time by contact with surrounding tissue fluids, by cellular activity, or other physiological degradation mechanisms), biodegradable (e.g., degraded over time by enzymatic or hydrolytic action, or other mechanisms in the body) or soluble materials may be used. Each of these terms is to be interpreted as interchangeable bioresorbable polymers. Potentially suitable bioresorbable materials include polylactic acid (PLA), poly(α-hydroxy acids) such as poly-L-lactide (PLLA), poly-D-lactide (PDLA), polyglycolide (PGA), polydioxanone, polycaprolactone, polyglucose ester, polylactic acid-polyethylene oxide copolymer, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphate, poly(amino acid) or related copolymer materials. An absorbable composite fiber can be made by combining a reinforcing fiber made of a copolymer of about 18% glycolic acid and about 82% lactic acid and a matrix material composed of a blend of the above copolymer and about 20% polycaprolactone (PCL).

[0114] The permeable shell embodiment 40, 140 can be formed at least in part from a wire, ribbon or other filamentary element 14, 114. These filamentary elements 14 can have a circular, elliptical, oval, square, rectangular or triangular cross-section. The permeable shell embodiment 40 can also be formed using conventional machining, laser cutting, electrical discharge machining (EDM) or photochemical machining (PCM). If made of metal, it can be made from a metal tube or sheet.

[0115] The device embodiments 10, 110 discussed herein can be delivered and deployed from a delivery and positioning system 112 including a microcatheter 61, such as a type of microcatheter 61 known in the field of neurovascular navigation and treatment. The device embodiments 10, 110 for treating a patient's vascular system can be elastically folded and constrained by a tube or other radial constraint (e.g., the lumen 120 of the microcatheter 61) for delivery and deployment. The microcatheter 61 can typically be inserted through a small incision 152 that enters a peripheral blood vessel, such as a femoral artery or a brachial artery. The microcatheter 61 can be delivered or otherwise navigated to a desired treatment site 154 from a location outside the patient's body 156 via a guidewire 159 under fluoroscopy or by other suitable guidance methods. The guidewire 159 can be removed during such a procedure to allow the device 10, 110, which is fixed to the delivery device 111 of the delivery system 112, to be inserted through the lumen 120 of the microcatheter 61 in some cases. Fig.17 Shows that it is accepting Fig.18 A schematic diagram of a patient 158 ​​is shown for treatment of a vascular defect 160. An access sheath 162 is shown disposed within a radial artery 164 or a femoral artery 166 of the patient 158, wherein a delivery system 112 includes a microcatheter 61 and a delivery device 111 disposed within the access sheath 162. The delivery system 112 is shown extending distally into the vasculature of the patient's brain adjacent to the vascular defect 160 in the patient's brain.

[0116] Access to various blood vessels of the patient can be established, including arteries such as the femoral artery 166, radial artery 164, etc., in order to achieve percutaneous access to the vascular defect 160. Generally speaking, the patient 158 ​​can be prepared for surgery and the access artery is exposed through a small surgical incision 152 and access to the lumen is obtained using the Seldinger technique, where a wire is placed using an introducer needle, a dilator or a series of dilators are placed thereon to dilate the vessel allowing the introduction sheath 162 to be inserted into the vessel. This will allow the device to be used percutaneously. With the guide sheath 162 in place, a guide catheter 168 is then used to provide safe passage from the access site to the area near the target site 154 to be treated. For example, when treating a site in the human brain, a guide catheter 168 will be selected that will extend from the entry site 152 at the femoral artery upward through the aorta extending around the heart through the aortic arch, and downward through one of the arteries extending from the upper side of the aorta, such as the carotid artery 170. Typically, the guidewire 159 and neurovascular microcatheter 61 are then placed through the guide catheter 168 and advanced through the patient's vascular system until the distal end 151 of the microcatheter 61 is positioned adjacent to or within the target vascular defect 160 (e.g., an aneurysm). Exemplary guidewires 159 for neurovascular use include Synchro2® manufactured by Boston Scientific and Glidewire Gold Neuro® manufactured by MicroVention Terumo. Typical guidewire sizes may include 0.014 inches and 0.018 inches. Once the distal end 151 of the catheter 61 is positioned at the site, the catheter is visualized, typically by using radiopaque marking material and fluoroscopy to locate its distal end. For example, if the guidewire 159 has been used to locate the microcatheter 61, it is withdrawn from the catheter 61 and the implant delivery device 111 is then advanced through the microcatheter 61.

[0117] The delivery and deployment of the device embodiments 10, 110 discussed herein can be accomplished by first compressing the device 10, 110 into a Figure 1 The device 10, 110 can then be delivered to the desired treatment site 154 while disposed within the microcatheter 61 and then expelled or otherwise deployed from the distal end 151 of the microcatheter 61. In other method embodiments, the microcatheter 61 can first be navigated to the desired treatment site 154 via a guidewire 159 or by other suitable navigation techniques. The distal side of the microcatheter 61 can be positioned so that the distal port of the microcatheter 61 is directed or disposed within the vascular defect 160 to be treated, and the guidewire 159 is withdrawn. The device 10, 110, secured to a suitable delivery device 111, can then be radially constrained, inserted into the proximal portion of the lumen 120 of the microcatheter 61 and advanced distally through the lumen 120 to the vascular defect 160.

[0118] Once disposed within the vascular defect 160, the device 10, 110 can then be allowed to assume an expanded relaxed or partially relaxed state, wherein the permeable shell 40, 140 of the device spans or partially spans a portion of or the entire vascular defect 160. For some embodiments, the device 10, 110 can also be activated by applying an energy source to assume an expanded, expanded configuration upon expulsion from the distal portion of the microcatheter 61. Once the device 10 is deployed at the desired treatment site 154, the microcatheter 61 can be withdrawn.

[0119] Some embodiments of the apparatus 10, 110 for treating a patient's vascular system discussed herein may be directed to treating a specific type of defect in the patient's vascular system. Fig.18 , an aneurysm 160, often referred to as a terminal aneurysm, is shown in cross-section. Terminal aneurysms typically occur at a bifurcation in a patient's vascular system, where blood flow from a supply vessel, indicated by arrows 172, splits into two or more branching vessels that move away from each other. The main blood flow from a supply vessel 174, such as the basilar artery, sometimes impinges on the vessel at the bifurcation and where the aneurysm pocket is formed. Terminal aneurysms may have a well-defined neck structure, where the contour of the aneurysm 160 narrows about the nominal vessel contour, but other terminal aneurysm embodiments may have a less well-defined neck structure or no neck structure. Fig.19 A typical berry aneurysm 160 is shown in cross section, where a portion of the wall of the nominal vessel portion weakens and expands into a bag-like structure that expands away from the nominal vessel surface and contours. Some berry aneurysms may have a well-defined neck structure, such as Fig.19 , but other aneurysms may have a less well-defined neck structure or none at all. Fig.19 Also shown are some optional procedures in which a stent 173 or other type of support has been deployed in a parent vessel 174 adjacent to the aneurysm. In addition, an embolic material 176 is shown deposited into the aneurysm 160 via the microcatheter 61. Either or both of the stent 173 and the embolic material 176 may be so deployed before or after the device 10 for treating the patient's vasculature is deployed.

[0120] Prior to delivering and deploying a device 10, 110 for treating a patient's vascular system, the treating physician may need to select an appropriately sized device 10, 110 to optimize treatment outcomes. Some embodiments of treatment may include estimating the volume of the vascular site or defect 160 to be treated and selecting a device 10, 110 having a volume that is substantially the same as or slightly larger than the volume of the vascular site or defect 160. The volume of the vascular defect 160 to be occluded may be determined using three-dimensional angiography or other similar imaging techniques and software that calculates the volume of the selected area. The amount of oversizing may be between approximately 2% and 15% of the measured volume. In some embodiments, such as very irregularly shaped aneurysms, it may be desirable to reduce the volume of the device 10, 110. Lobules or "sub-aneurysms" may be excluded from the volume, defining a cutoff volume that may be only partially filled by the device without affecting the outcome. Devices 10, 110 deployed within such irregularly shaped aneurysms 160 are discussed below. Fig.28 . Such method embodiments may also include implanting or deploying the device 10, 110 such that the vascular defect 160 is substantially volumetrically filled by the combination of the device and the blood contained therein. The device 10, 110 may be configured to be sufficiently conformable to accommodate an irregularly shaped vascular defect 160 such that at least about 75%, in some cases about 80%, of the volume of the vascular defect is occluded by the combination of the device 10, 110 and the blood contained therein.

[0121] In particular, for some therapeutic embodiments, it may be desirable to select a device 10, 110 that is appropriately oversized in the transverse dimension in order to achieve the desired compliance, radial force, and fit after the device 10 is deployed. Figure 20-22 Schematic diagram showing how the device 10, 110 may be selected for proper fit after deployment, with the device initially being oversized in transverse dimension by at least about 10%, and sometimes even greater than about 100%, of the maximum transverse dimension of the vascular defect 160. For some embodiments, the device 10, 110 may be oversized by a small amount (e.g., less than about 1.5 mm) relative to the measurements of the width, height, or neck diameter of the vascular defect 160.

[0122] exist Fig. 20 , a vascular defect 160 in the form of a cerebral aneurysm is indicated by horizontal arrows 180 and vertical arrows 182, showing the approximate maximum internal dimensions of the defect 160. The horizontally extending arrow 180 indicates the maximum transverse dimension of the defect 160. Fig.21 , a dashed outline 184 of a device for treating a vascular defect is shown superimposed on Fig. 20 1, showing the appearance of the device 10, 110 in its unconstrained relaxed state, which has been selected to have a transverse dimension that is approximately 20% oversized. Fig. 22 Shown by Fig.21 The dashed line 184 indicates how the device 10, 110 may conform to the interior surface of the vascular defect 160 after deployment, whereby the nominal transverse dimension of the device 10, 110 in a relaxed, unconstrained state has now been slightly constrained by the inward radial force 185 exerted on the device 10, 110 by the vascular defect 160. In response, because the filaments 14, 114 of the device 10, 110, and the permeable shell 40, 140 formed therefrom, have a constant length, the device 10, 110 assumes a slightly elongated shape in the axial or longitudinal axis of the device 10, thereby elongating and better filling the interior volume of the defect 160, as shown. Fig. 22 As shown by the downward arrow 186 in FIG.

[0123] Once the appropriately sized device 10, 110 is selected, the delivery and deployment process can then proceed. It should also be noted that the features of the device embodiments 10, 110 and delivery system embodiments 112 discussed herein generally allow for the retrieval of the device 10 after initial deployment into the defect 160 but prior to detachment of the device 10, 110. Thus, it is possible and desirable to withdraw or retrieve the initially deployed device 10 after evaluating the fit within the defect 160 to support a different sized device 10, 110. An example of a terminal aneurysm 160 is shown in FIG. Fig.23 The tip 151 of a catheter, such as a microcatheter 61, can be advanced into or near a vascular site or defect 160 (such as an aneurysm), such as Fig.24 For some embodiments, an embolic coil or other vascular occlusive device or material 176 (e.g., Fig.19 10, 110. In addition, prior to or during delivery of the devices discussed herein for treating the vascular system of a patient, a stent 173 may be placed in a parent vessel 174 of some aneurysms that substantially traverse the neck of the aneurysm (e.g., also shown in FIG. Fig.19). An example of a suitable microcatheter 61 having an inner lumen diameter of about 0.020 inches to about 0.022 inches is the Rapid Transit® manufactured by Cordis Corporation. Some examples of suitable microcatheters 61 may include microcatheters having an inner lumen diameter of about 0.026 inches to about 0.028 inches, such as Rebar® by Ev3, Renegade Hi-Flow® by Boston Scientific, and Mass Transit® by Cordis. Suitable microcatheters having an inner lumen diameter of about 0.031 inches to about 0.033 inches may include Marksmen® by Chestnut Medical Technologies, Inc. and Vasco 28® by Balt Extrusion. Suitable microcatheters 61 having an inner lumen diameter of about 0.039 inches to about 0.041 inches include Vasco 35 by Balt Extrusion. These microcatheters 61 are listed as exemplary embodiments only, and other suitable microcatheters may also be used with any of the embodiments discussed herein.

[0124] The detachment of the device 10, 110 from the delivery device 111 can be controlled by a control switch 188 disposed at the proximal end of the delivery system 112, which can also be connected to an energy source 142 that cuts the tether 72 that secures the proximal hub 68 of the device 10 to the delivery device 111. When deployed within a microcatheter 61 or other suitable delivery system 112, reference is made to Fig.11 , the filaments 14, 114 of the permeable shell 40, 140 can assume an elongated, non-everted configuration, substantially parallel to each other and to the longitudinal axis of the catheter 61. Once the device 10, 110 is pushed out of the distal port of the microcatheter 61, or the radial constraint is otherwise removed, the distal ends 62 of the filaments 14, 114 can then be axially contracted toward each other, thereby assuming a spherical everted configuration within the vascular defect 160, as shown. Fig.25 shown.

[0125] The device 10, 110 can be inserted through the microcatheter 61 such that the catheter lumen 120 limits radial expansion of the device 10, 110 during delivery. Once the distal tip or deployment port of the delivery system 112 is positioned at a desired location near or within the vascular defect 160, the device 10, 110 can be deployed out of the distal end of the catheter 61, thereby allowing the device to begin radial expansion, such as Fig.25 When the device 10 , 110 emerges from the distal end of the delivery system 112 , the device 10 , 110 expands to an expanded state within the vascular defect 160 , but may be at least partially constrained by the inner surface of the vascular defect 160 .

[0126] When fully deployed, radial expansion of the device 10, 110 may be used to secure the device 10, 110 within the vascular defect 160 and also deploy the permeable shell 40 across at least a portion of the opening 190 (e.g., an aneurysm neck) to at least partially isolate the vascular defect 160 from flow, pressure, or both of the patient's vasculature adjacent to the vascular defect 160, as described herein. Fig.26 As shown. The conformability of the device 10, 110, particularly in the neck region 190, can provide an improved seal. For some embodiments, once deployed, the permeable shell 40, 140 can significantly slow the flow of fluid and prevent fluid from flowing into the vascular site, thereby reducing the pressure within the vascular defect 160. For some embodiments, the device 10, 110 can be implanted substantially within the vascular defect 160, however, in some embodiments, a portion of the device 10, 110 can extend into the defect opening or neck 190 or branch vessels.

[0127] For some embodiments, as described above, during or after deployment but before detachment, the device 10, 110 can be manipulated by a user to position the device 10, 110 within a vascular site or defect 160. For some embodiments, the device 10, 110 can be rotated to achieve a desired position of the device 10, and more specifically, a desired position of the permeable shell 40, 140, 240, 340, 440, before or during deployment of the device 10, 110. For some embodiments, the device 10, 110 can be rotated about the longitudinal axis of the delivery system 112 with or without torque transmission or performance presented along the middle portion of the delivery catheter for delivery. In some cases, it may be desirable to determine whether acute occlusion of the vascular defect 160 has occurred before the device 10, 110 is detached from the delivery device 111 of the delivery system 112. These delivery and deployment methods can be used for deployment within a berry aneurysm, a terminal aneurysm, or any other suitable vascular defect embodiment 160. Some method embodiments include deploying the device 10, 110 at the confluence of three vessels of the patient's vascular system forming a bifurcation such that the permeable shell 40, 110 of the device 10 substantially covers the neck of the terminal aneurysm. Once the physician is satisfied with the deployment, size, and position of the device 10, 110, the device 10, 110 can then be deployed as described above and Fig.26 The device 10, 110 is shown separated by actuation of the control switch 188. Thereafter, the device 10, 110 is in an implanted state within the vascular defect 160 to achieve treatment thereof.

[0128] Fig. 27 Another configuration of a device deployed and implanted in a vascular defect 160 of a patient is shown. Fig.26The implant configuration shown indicates a configuration whereby the longitudinal axis 46 of the device 10, 110 is substantially aligned with the longitudinal axis of the defect 160, but other suitable and clinically effective implant embodiments may be used. Fig. 27 An implant embodiment is shown in which the longitudinal axis 46 of the implant device 10, 110 is inclined at an angle of about 10 degrees to about 90 degrees relative to the longitudinal axis of the target vascular defect 160. This alternative implant configuration may also be useful in achieving a desired clinical outcome in certain circumstances by providing acute occlusion of the vascular defect 160 and restoring normal blood flow in the vicinity of the treated vascular defect. Fig.28 The device 10, 110 is shown implanted in an irregularly shaped vascular defect 160. The aneurysm 160 shown has at least two distinct leaves 192 extending from the aortic aneurysm cavity. The two leaves 192 are not filled by the deployed vascular device 10, 110, but due to the occlusion of the aneurysm neck 190, the leaves 192 are still isolated from the parent vessel of the patient's body.

[0129] Markers, such as radiopaque markers, on the device 10, 110 or delivery system 112 can be used in conjunction with external imaging equipment (e.g., x-ray) to facilitate positioning of the device or delivery system during deployment. Once the device is properly positioned, the device 10 can be detached by the user. For some embodiments, detachment of the device 10, 110 from the delivery device 111 of the delivery system 112 can be affected by the delivery of an engagement or release mechanism energy (e.g., heat, radiofrequency, ultrasound, vibration, or laser) to a connection or release mechanism between the device 10 and the delivery device 111. Once the device 10, 110 has been detached, the delivery system 112 can be withdrawn from the patient's vascular system or the patient's body 158. For some embodiments, after delivery of the device 10, the stent 173 can be placed substantially within the parent vessel across the aneurysm neck 190, such as Fig.19 shown.

[0130] For some embodiments, a bioactive agent or passive therapeutic agent may be released from the responsive material component of the device 10, 110. Agent release may be affected by one or more body environmental parameters, or energy may be delivered to the device 10, 110 (from an internal or external source). Due to the isolation of the vascular defect 160, hemostasis may occur within the vascular defect 160, ultimately leading to coagulation and substantial occlusion of the vascular defect 160 by the combination of the thrombogenic material and the device 10, 110. For some embodiments, thrombosis within the vascular defect 160 may be promoted by agents released from the device 10 and / or drugs or other therapeutic agents delivered to the patient.

[0131] For some embodiments, once the device 10, 110 has been deployed, platelet adhesion to the permeable shell 40 can be inhibited and clot formation within the interior space of the vascular defect 160, the device, or both can be promoted or otherwise facilitated by appropriate selection of a thrombogenic coating, an antithrombotic coating, or any other suitable coating (not shown), which can be disposed on any portion of the device 10, 110, including, for some embodiments, the outer surface of the hubs 66 and 68 or the wire 14. Such one or more coatings can be applied to any suitable portion of the permeable shell 40. For some embodiments, energy forms can also be applied by the delivery device 111 and / or a separate catheter to promote fixation and / or healing of the device 10, 110 adjacent to the vascular defect 160. One or more embolic devices or embolic materials 176 can also be optionally delivered into the vascular defect 160 adjacent to the permeable shell portion that spans the neck or opening 190 of the vascular defect 160 after the device 10 has been deployed. For some embodiments, the stent or stent-like support device 173 may be implanted or deployed in a parent vessel adjacent to the defect 160 such that it spans the vascular defect 160 before or after the vascular defect treatment device 10, 110 is deployed.

[0132] In any of the above embodiments, the device 10, 110 may have sufficient radial compliance to be easily retrieved or retracted into a typical microcatheter 61. The proximal portion of the device 10, 110, or for some embodiments the device as a whole, may be designed or modified by using reduced diameter wires, tapered wires, or wires oriented for radial bending so that the device 10, 110 can be retracted into a tube having an inner diameter of less than about 0.7 mm using a contraction force of less than about 2.7 Newtons (0.6 lbf). The force used to retract the device 10, 110 into the microcatheter 61 may be between about 0.8 Newtons (0.18 lbf) and about 2.25 Newtons (0.5 lbf).

[0133] When in the expanded relaxed state, engagement of the permeable shell 40, 140 with the tissue of the inner surface of the vascular defect 160 may be achieved by applying an outward radial force to the tissue of the inner surface of the lumen of the patient's vascular defect 160, e.g. Fig.29as shown. Similar outward radial forces may also be applied by the proximal portion of the device 10, 110 and the permeable shell 40, 140 to engage the permeable shell 40 with the inner surface of the vascular defect 160 or adjacent tissue. Such forces may be applied in some embodiments where the nominal outer transverse dimension or diameter of the permeable shell 40 in a relaxed, unconstrained state is greater than the nominal inner transverse dimension of the vascular defect 160 in which the device 10, 110 is deployed, i.e., oversized as described above. The elasticity of the permeable shell 40 and its filaments 14 may be achieved by appropriate selection of materials, such as superelastic alloys, including nickel-titanium alloys, or any other suitable material for certain embodiments. The conformability of the proximal portion of the permeable shell 40, 140 of the device 10, 110 may allow it to be easily ovated to accommodate the shape and size of the aneurysm neck 190, such as Figure 20-22 As shown, a good seal and barrier is provided for flow around the device. Thus, the device 10 can achieve a good seal, substantially preventing flow around the device without requiring a fixation member protruding into the parent vessel.

[0134] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced which will still fall within the scope of the appended claims.

Claims

1. A device for treating a cerebral aneurysm in a patient, comprising: an elastic self-expandable permeable shell comprising a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state having a longitudinally shortened configuration relative to the radially constrained state, and a plurality of filaments braided together to form a mesh and define a lumen of the permeable shell, Wherein the expanded state has a proximal portion and a distal portion, and wherein the proximal portion includes at least one coil connected to the mesh.

2. The device according to claim 1, wherein: The at least one coil surrounds or is coupled to at least a portion of one of the plurality of wires.

3. The device according to claim 1, wherein: The at least one coil has a helical shape.

4. The device according to claim 1, wherein: The at least one coil comprises a hydrogel.

5. The device according to claim 1, wherein: The number of the at least one coil is selected from the group consisting of about 2 to about 10, about 3 to about 12, about 4 to about 8, about 5 to about 10, about 5 to about 15, about 2 to about 30, and about 2 to about 25.

6. The device according to claim 1, wherein: The proximal portion has a greater radial stiffness than a distal portion of the permeable shell.

7. The device according to claim 1, wherein: The radial stiffness of the proximal portion is 1.5 to 3 times the radial stiffness of the distal portion of the permeable shell.

8. A device for treating a cerebral aneurysm in a patient, comprising: an elastic self-expandable permeable shell comprising a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state having a longitudinally shortened configuration relative to the radially constrained state, and a plurality of filaments braided together to form a mesh and define a lumen of the permeable shell, Wherein the expanded state has a proximal portion and a distal portion, and wherein the proximal portion includes one or more reinforcing elements to increase proximal stiffness of the device.

9. The device according to claim 8, wherein: The one or more reinforcing elements surround or are coupled to at least a portion of a filament in the plurality of filaments.

10. The device according to claim 8, wherein: The one or more reinforcing elements have a helical shape.

Images